摘要
Abstract
Objective To observe the curative effect of Sulodexide combined with Beraprost sodium in treatment of diabetic nephropathy (DN). Methods A total of 96 cases of DN in our hospital were divided randomly into 3 groups, 32 cases for each group. On the basis of conventional therapy, the groups were further divided into Sulodexide group (oral Sulodexide), Beraprost sodium group (oral Beraprost sodium) and combination group (oral Sulodexide and Beraprost sodium). The clinical efficacy of the 3 groups were observed after 8 weeks of treatment. Levels of 24-hour urine protein quantitative (24 h-UTP), urine albumin excretion rate (UAER), urine 2 microspheres protein (2-MG), serum cystatin C (Cys C), fibrinogen (FIB), plasma plasminogen activator inhibitor 1 (PAI-1) and D-Dimer (D-D) were observed pre- and post-treatment. Results Eight weeks later, the clinical efficacy of combination group was compared with Sulodexide group and Beraprost sodium group, but there was no significant difference, respectively (P ＞ 0.05). Post-treatment levels of 24 h-UTP, UAER and Cys C in Sulodexide group, 24 h-UTP, 2-MG and Cys C in Beraprost sodium group and UAER, 24 h-UTP, Cys C and 2-MG in combination group decreased significantly than their pre-treatment ones (P ＜ 0.05), respectively. Eight weeks later, there were significant differences for levels of 24 h-UTP, 2-MG, FIB and D-D in combination group compared with Sulodexide group (P ＜ 0.05); there were significant differences for 24 h-UTP, UAER, FIB and D-D in combination group compared with Beraprost sodium group (P ＜ 0.05). Conclusions Sulodexide combined with Beraprost sodium in treatment of DN can reduce the formation of urinary protein effectively, improve the renal vascular high coagulation state and fibrinolytic activity, delay the progress of DN and protect kidney. Meanwhile, the side effects are less, which is an effective treatment of DN.关键词
舒洛地特/贝前列素钠/糖尿病肾病/疗效Key words
Sulodexide/Beraprost sodium/diabetic nephropathy/curative effect分类
医药卫生
